7.45
-0.50 (-6.23%)
| Previous Close | 7.94 |
| Open | 7.39 |
| Volume | 2,306,945 |
| Avg. Volume (3M) | 1,496,374 |
| Market Cap | 739,293,376 |
| Price / Sales | 7.78 |
| Price / Book | 12.62 |
| 52 Weeks Range |
| Profit Margin | -16.11% |
| Operating Margin (TTM) | -466.29% |
| Diluted EPS (TTM) | -0.160 |
| Quarterly Revenue Growth (YOY) | 4,900.00% |
| Total Debt/Equity (MRQ) | 30.33% |
| Current Ratio (MRQ) | 11.00 |
| Operating Cash Flow (TTM) | -20.48 M |
| Levered Free Cash Flow (TTM) | -9.60 M |
| Return on Assets (TTM) | -6.10% |
| Return on Equity (TTM) | -6.91% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | ARS Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | 0.25 |
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 16.93% |
| % Held by Institutions | 80.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Orbimed Advisors Llc | 31 Mar 2026 | 8,288,510 |
| Sr One Capital Management, Lp | 31 Mar 2026 | 4,012,903 |
| Tyro Capital Management Llc | 31 Mar 2026 | 2,968,599 |
| Janney Montgomery Scott Llc | 31 Mar 2026 | 2,016,464 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |